Introduction
Breast cancer is a highly heterogeneous disease that has multiple subtypes with distinct clinical outcomes. Clinically, breast cancers are classified by hormone receptor status, including expression of estrogen receptor (ER), progesterone receptor (PR), and human EGFlike receptor type 2 (HER2) receptor (1) . Oncogenes such as FGF-3, FGF-4, Cyclin D1 (PRAD-1), HER2, N-RAS, c-Myc, BRCA1, and BRCA2 have a high correlation with breast cancer. Fibroblast growth factor 3/4 (FGF3/4) is member of the fibroblast growth factor (FGF) families. FGF families are involved in mitogenic, cell survival activities, biological processes, cell growth, morphogenesis, tissue repair, tumor growth, and invasion (2) . Frequent amplification of this FGF family gene has been found in human tumors, which may be important for neoplastic transformation and tumor progression (2) . RAS-gene family is associated with a variety of human cancer. N-RAS is an oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane (3) . This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex (4) . A variable form of RAS is mainly found in the growth sites of breast cancer epithelial cells. Mutation of this gene, easily happen on the amino acid residues 12 and 13, promotes the cell transformation (5) . Cyclin D1, which is also known as PRAD-1, forms a complex and works as a regulatory subunit of CDK4 or CDK6 (6) . Cyclin D1 is required for cell cycle G1/S transition (7) . Mutation, amplification, and over-expression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis (7) . Cyclin D1 over-expression is strongly correlated to ER(+) breast cancer and deregulation of cyclin D1 is associated with hormone therapy resistance in breast cancer (8) . Human epidermal growth factor receptor type 2 (HER2) overexpression has been known to play an important role in the development and progression of breast cancer (9) . c-Myc is involved that regulation of cellular proliferation, differentiation, apoptosis, and angiogenesis (10) . Over-expression of c-Myc was found to be associated with its amplification, suggesting that c-Myc amplification may have a key oncogenic role in the pathology of breast cancer (10) . Breast Cancer 1/2 (BRCA1/BRCA2) act as a tumor suppressor encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability (11) . BRCA1/BRCA2 associates with RNA polymerase II by the c-terminal domain and also interacts with histone deacetylase complexes (11) . Thus, this protein plays a role in transcription, DNA repair of double-stranded breaks, and recombination.
MicroRNAs (miRNAs) are a class of non-coding small RNA molecules (20-25 nucleotides) that negatively regulate the gene expression by binding their target mRNA. Lin-4, the first miRNA, discovered by the Victor Ambros group in 1993 and this small molecule regulates the generation time of Caenorhabditis elegans (C. elegans) by affecting the synthesis of LIN-14 protein. The miRNAs comprise 1 to 3% of human genome but they are known to regulate more than 30% of human genes (12) . The miRNAs have been known to control the cell growth, differentiation, cell proliferation, cell-cycle, apoptosis, and carcinogenesis (13) . Interestingly, change of miRNA expression is related with various diseases (14) . A single miRNA can regulate a variety of target genes and a single gene can be simultaneously regulated by multiple miRNAs vice versa (13, (15) (16) (17) . In this aspect, the miRNAs may have a co-targeting network with their multi-targeting capability. However, most of studies demonstrated validation of single miRNA-single target. These studies require a lot of time and cost (18) . In an era of big data, we already have vast data such as miRNA expression profiling and predicted or validated miRNA-target data. Amount of accumulating biological data give us opportunity to find a new valuable meanings. Therefore, analyzing tool and method that can extract refined data from bulk data are very important to understand biological complexity and to find new meaning. A number of array-platform-based studies showed that miRNA expression profiling results between array studies are not consistent and huge (19) . Compared to miRNA array-platform, the miRNA deep sequencing technology provides massive results of genome-widely expressed miRNAs, expression level of individual miRNAs, and novel miRNAs.
The Cancer Genome Atlas (TCGA), open access portal is a research network that has analyzed large number of human cancer sample related with DNA, RNA, protein, and miRNA. The TCGA miRNA sequencing data includes resource for both tumor and adjacent normal samples clinically. Big data about miRNA expression change in human sample which is obtained from the TCGA offer better information of miRNAs dysregulation in breast cancer. Changed miRNAs may mean reliable biomarker and potential therapeutic targets (20) . To understand the mechanism of miRNA regulation, we need targets that are regulated by changed miRNAs. The miRNAs usually bind to the 3'-untranslated region (3'UTR) of their mRNA target and this condition triggers the repression of translation or degradation of the target according to the complementary sequencing match between the target 3'UTR and seed site of miRNA. Many of algorithms, like mirWalk (21), Miranda (22) , mirDB (23), RNA22 (24) , and TargetScan (25) seek putative miRNA for given target sequences based on canonical miRNA binding. However, since these programs have slightly different criteria, each of them predicts different results (26) . So, finding a functional miRNA and their target is a challenging. To identify more reliable putative miRNA and target, we need a cross-check between available data bases. In this study, we were focusing on the regulation networking of miRNAs which can regulate multi-oncogenes. The aim of this study was to elucidate the common miRNAs among the target oncogenes which may be critical resource for breast cancer chemoprevention.
Materials and Methods
miRNA bulk data collection from human cancer sample TCGA (http://cancergenome.nih.gov) provides opportunity for researchers to download a wide range of information by analyzing the clinical cancer sample. Five columns to select such as cancer type, center, platform, data type, and archive type exist in the section of bulk download. We chose breast invasive carcinoma as cancer type and used the Illumina Genome Analyzer miRNA sequencing as platform in the column. There are four types of information: miRNA ID, read count, reads per million (RPM), and cross-mapped.
miRNA sequencing data contain the quantitative expression levels of miRNA that are computed based on the read counts in one sample. For comparison of miRNA expression in two or more samples, expression levels in each sequenced sample are normalized by the total number of reads in the sample. RPM is a value of normalized expression level that were produced for each sample. Therefore, we use miRNA ID and RPM because we need an expression level of miRNAs in data.
Sorting Single-molecule-based platforms such as Illumina Genome analyzer platform usually show an inherent high error because this platform detected all sequences containing the errors. High error rates cause low read counts. According to the difference of miRNA expression level above five-folds (≥5), two and half-folds (≥2.5), and another (<2.5), the miRNA IDs were divided into 3 groups. The low level expression (<2.5) and/or no changes miRNA IDs in the collected bulk data were removed to avoid error.
Double-checking
The mirWalk is supporting not only a documentary system of predicted miRNA-target interactions, but also comparing this information with another miRNA-target prediction programs (DIANA-microT, miranda, miRBridge, miRDB, miRmap, miRNA Map, PITA, RNA22, and Targetscan). To investigate the interaction of miRNA IDs and molecular target, the available miRNA IDs were double-checked through five reliable D/Bs (miRWalk, miRanda, miRDB, RNA22, and TargetScan). Based on the SUM value, over 3 in the five D/Bs, miRNA IDs is sorting subject in this study. By doublechecking with comparing five D/Bs, we could obtain three facts. The first thing was a correlation between target gene and miRNA IDs. The second thing was reliability of predicted miRNAs belong to the specific gene. The last thing was completed removal of meaningless miRNA IDs.
Clustering Each target gene have multiple miRNA IDs that expressed over five-folds (≥5), two and half-folds (≥2.5), and below that. Extracted miRNAs were speculated that those are the oncogenic miRNAs which may promote the breast carcinogenesis via target gene. Each miRNA ID data was clustering to drain the common one Table 1 which will be more effective and new target for breast cancer prevention.
Results and Discussion
The breast cancer is mainly related with estrogen receptor, progesterone receptor, and HER2 receptor. We selected 8 oncogenes (BRCA1, BRCA2, HER2, Cyclin D1, N-RAS, FGF3, FGF4, and c-Myc) and their miRNAs have high correlation molecular target for breast cancer. Table 1 has raw data about breast cancer downloaded by TCGA. Predicted miRNA list concerning the each oncogenes are classified according to the expression level ( Table 2 to 5). Putative miRNA list that may regulate the BRCA1 are as follows: miRNA above five-folds (≥5) occupied 11% [52 miRNAs] of the total followed by two and halffolds (≥2.5) occupied 1.5% [7 miRNAs ] and regulate the BRCA2 above five folds (≥5) occupied 5% [26 miRNAs] of the total followed by two and half-folds (≥2.5) occupied 0.4% [2 miRNAs] ( Table 2 ). In the Table  3 , Cyclin D1 regulating miRNAs were suggested that above five-folds (≥5) occupied 18% [83 miRNAs] of the total followed by two and halffolds (≥2.5) occupied 2% [9 miRNAs]. Regarding oncogene N-RASregulating miRNAs were listed up Table 4 , miRNAs above five-folds (≥5) occupied 23% [102 miRNAs] of the total followed by two and half-folds (≥2.5) occupied 2.9% [13 miRNAs]. Although there was a no universal miRNA targeting all 8 oncogenes, however, there were revealed some meaningful common miRNAs. As illustrated in Table 6 , results of overlapped common miRNAs among the 8 oncogenes showed that 28 miRNAs were commonly regulating three above oncogenes target. Let-7c is controlling the 5 oncogenes (BRCA1, BRCA2, HER2, N-RAS, and Cyclin D1) among the miRNA above five-folds occupied. In five-folds (≥5) raw data 4 miRNAs, let-7g, miR-186, miR-589, and miR-224 were commonly regulating among four oncogenes target. 21 miRNAs (let-7b, let-7e, let-7i, miR-30d, miR-93, miR-205, miR-106b, miR-146b, miR-424, miR-17, miR-20a, miR-146a, miR-20b, miR-769, miR-26a-1, miR106a, miR-625, miR-98, miR-19a, miR-3613, and miR-361) were commonly regulating among three oncogenes target. In Table 6 , in two and half-folds (≥2.5) raw data miR-651 was repeating on targeting the 3 oncogenes (BRCA1, BRCA2, and Cyclin D1). miR-1468 was also repeating 3 oncogenes (BRCA1, N-RAS, and c-Myc).
The miRNA can regulate many cell mechanisms, including cell growth, cell proliferation, cell-cycle, apoptosis, and carcinogenesis (13) . Over-expressed miRNA in specific diseases suggest that miRNA can promote related diseases via suppressing target gene (27) . Since the disease specific-miRNA is found, miRNA is receiving attention as a potential chemoprevention agent (27) . It is important to understanding the biological role of miRNA which regulate their corresponding mRNA targets. However, due to the various miRNAs and potential targets, validating the miRNA-target would be extremely difficult and not economical. Various computational analysis methods have been generated the putative miRNA target. The miRNA data base such as miRWalk, miRanda, miRDB, RNA22, and TargetScan provide predicted miRNA-target data and use different algorithm. These programs often predict distinct miRNA target. Kuhn et al. (28) reported that when Angiotensin II Receptor Type 1 (AGTR1) was analyzed for identifying predicted miRNA, miRanda predicted 27 miRNA within the AGTR1 3'-UTR and TargetScan showed 37 miRNA. In contrast to two data base, PicTar show no miRNA list. Therefore, cross-checking the bioinformatics tools are essential for more accurate prediction. We conduct data mining to elucidate common miRNA which regulate multi-oncogene.
Because bulk data provided by TCGA contains over-expressed miRNA information from clinical breast cancer sample, it can be a new tool to increase the accuracy and specificity of computational methods. Selected 8 oncogenes have more high correlation with breast cancer. So, when we investigated the miRNA predicted data base, genemiRNA target module is used inversely. Adding the clinical information and process of cross-check with inverse target module between the miRNA data base, data mining would be more reliable. Elucidated common miRNAs means that they are likely to be more effective than miRNA provided from previous study, because common miRNAs control the multi-gene related with breast cancer and have regulation-networking among the miRNAs. In general, there are two approaches to applying miRNA as a therapeutic or biomarker. Anti-miRNA oligonucleotides (AMOs) are blocking reagents that inhibit the activity of mature miRNA by hybridizing and sense oligonucleotides (mimics) are double-stranded miRNA-like RNA fragment. The miRNA-based therapeutic has already passed Phase 2 clinical trials (29) (30) (31) (32) . Altered miRNAs can be utilized for diagnosis and prognosis of a variety of diseases, such as cancer, cardiovascular, inflammatory, and neurodevelopmental disease (33, 34) . However, there is a little interest about miRNA utilizing for food or animal feed. Various food components including Vitamin A, 
Vitamin B, Curcumin, Resveratrol, Ellagitannins, and Isoflavones can affect the miRNA expression (35) (36) (37) (38) (39) . These findings suggest that food components either indirectly participate in the physiologic process by regulating miRNA expression or directly regulate the physiologic process by itself. It is worthy to check the possibility of combination between the miRNA and food component, because of potential synergic effect. Plant is a main resource of food. Zhang et al. have demonstrated that ingested miRNAs through plant were detected in human serum and exogenous plant miR-168a specifically could inhibit mammalian low-density lipoprotein receptor adapter 1 (LDLRAP1) mRNA (40) . Indeed, exogenous plant miRNA were stable in cooked food and could endure the mouse G1 tract (40, 41) . Strategy of miRNAs-containing food may be an effective method for disease prevention by combination of miRNA and food components. This high-tech food can be achieved by using the ASO and/or mimic of miRNA that involved in specific disease. Common miRNA with multi-targeting ability will be a critical resource for development of food.
